AlzeCure Pharma AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALZCUR.ST research report →
Companywww.alzecurepharma.se
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain.
- CEO
- Martin Jönsson
- IPO
- 2018
- Employees
- 11
- HQ
- Huddinge, SE
Price Chart
Valuation
- Market Cap
- $160.31M
- P/E
- -2.71
- P/S
- 0.00
- P/B
- 14.28
- EV/EBITDA
- -2.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -234.11%
- ROIC
- -465.37%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-47,654,000 · -35.25%
- EPS
- $-0.47 · -2.17%
- Op Income
- $-49,371,000
- FCF YoY
- 1.86%
Performance & Tape
- 52W High
- $4.95
- 52W Low
- $1.30
- 50D MA
- $1.53
- 200D MA
- $2.18
- Beta
- -0.04
- Avg Volume
- 89.44K
Get TickerSpark's AI analysis on ALZCUR.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ALZCUR.ST Coverage
We haven't published any research on ALZCUR.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALZCUR.ST Report →